Article successfully added.

CyFlow™ IgD PE

CyFlow™ IgD PE
Antibody: Yes
Antigen: IgD
Application: Flow cytometry
Clonality: monoclonal
Clone: IA6-2
Emission Maximum: 576 nm
Excitation Maximum: 496 nm, 565 nm
Field of Interest: Immunoglobulins, Immunophenotyping
Format/Fluorochrome: PE
Isotype: IgG2a
Laser: Blue , Green, Yellow
Regulatory Status: RUO
Source Species: Mouse
Target Species: Human
Product number: BK989461

For Research Use Only

$255.00 USD*

Price excludes any applicable taxes plus shipping costs

Description Documentation TDS & SDS
Description
Quantity 100 tests Volume 1.0 mL Immunogen Human IgD Background Information... more
Close menu
CyFlow™ IgD PE
Quantity100 tests
Volume1.0 mL
ImmunogenHuman IgD
Background InformationImmunoglobulin D (IgD) is expressed on the surface of naive mature B cells, thus later than IgM, and is coexpressed with it then. Triggered by antigen binding, it signals through the CD79 complex to activate the B cells. Expression of IgD is lost after the isotype switch. Soluble IgD is present in very small amounts in the serum. IgD can bind to basophils and mast cells to activate them in an IgE-independent way to participate in respiratory immune defense.
UsageThe reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 10·µl reagent·/ 100·µl of whole blood or 10^6 cells in a suspension. The content of a vial (1 ml) is sufficient for 100 tests.
Storage BufferThe reagent is provided in stabilizing phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.
Specific References

| Baier G, Baier-Bitterlich G, Looney DJ, Altman A: Immunogenic targeting of recombinant peptide vaccines to human antigen‑presenting cells by chimeric anti‑HLA‑DR and anti‑surface immunoglobulin D antibody Fab fragments in vitro. J Virol. 1995 Apr; 69(4):2357‑65. < PMID: 7533857 > | Pugh-Bernard AE, Silverman GJ, Cappione AJ, Villano ME, Ryan DH, Insel RA, Sanz I: Regulation of inherently autoreactive VH4‑34 B cells in the maintenance of human B cell tolerance. J Clin Invest. 2001 Oct; 108(7):1061‑70. < PMID: 11581307 > | Ferrari S, Giliani S, Insalaco A, Al-Ghonaium A, Soresina AR, Loubser M, Avanzini MA, Marconi M, Badolato R, Ugazio AG, Levy Y, Catalan N, Durandy A, Tbakhi A, Notarangelo LD, Plebani A: Mutations of CD40 gene cause an autosomal recessive form of immunodeficiency with hyper IgM. Proc Natl Acad Sci USA. 2001 Oct 23; 98(22):12614‑9. < PMID: 11675497 > | Di Sabatino A1, Carsetti R, Rosado MM, Ciccocioppo R, Cazzola P, Morera R, Tinozzi FP, Tinozzi S, Corazza GR: Immunoglobulin M memory B cell decrease in inflammatory bowel disease. Eur Rev Med Pharmacol Sci. 2004 Sep-Oct; 8(5):199‑203. < PMID: 15638230 > | Chang NH, McKenzie T, Bonventi G, Landolt-Marticorena C, Fortin PR, Gladman D, Urowitz M, Wither JE: Expanded population of activated antigen‑engaged cells within the naive B cell compartment of patients with systemic lupus erythematosus. J Immunol. 2008 Jan 15; 180(2):1276‑84. < PMID: 18178868 > | Bunch DO, McGregor JG, Khandoobhai NB, Aybar LT, Burkart ME, Hu Y, Hogan SL, Poulton CJ, Berg EA, Falk RJ, Nachman PH: Decreased CD5+ B cells in active ANCA vasculitis and relapse after rituximab. Clin J Am Soc Nephrol. 2013 Mar; 8(3):382‑91. < PMID: 23293123 > | Degauque N, Ngono AE, Akl A, Lepetit M, Crochette R, Giral M, Lepourry J, Pallier A, Castagnet S, Dugast E, Guillot-Gueguen C, Jacq-Foucher M, Saulquin X, Cesbron A, Laplaud D, Nicot A, Brouard S, Soulillou JP: Characterization of antigen‑specific B cells using nominal antigen‑coated flow‑beads. PLoS One. 2013 Dec 30; 8(12):e84273. < PMID: 24386360 >

TDS & SDS
Close menu

Technical Data Sheet

Safety Data Sheet